Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2016 by Bristol-Myers Squibb
ICON Clinical Research
Molecular MD
Q2 solutions
Donald E. Morisky
MD Anderson Symptom Inventory (MDASI-CML)
OBiS, Inc
Steering Committee
Information provided by (Responsible Party):
Bristol-Myers Squibb Identifier:
First received: May 4, 2012
Last updated: October 7, 2016
Last verified: August 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: January 2022
  Estimated Primary Completion Date: January 2022 (Final data collection date for primary outcome measure)